LEGN241220P20000
- 0.05
- 0.000.00%
Legend Biotech Newsroom
25 U.S. 'Highest Conviction' Stocks – UBS
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(LEGN) - Analyzing Legend Biotech's Short Interest
Legend Biotech Management to Meet With Piper Sandler
China to Lift Fiscal Spending to Boost Economy
China Central Economic Work Conference: A Key Indicator for Future Market Trends
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment
Genscript Bio (01548.HK): Legend Biotech announces the release of a report at the 2024 ASH annual meeting.
On December 10, Guolonghui reported that GENSCRIPT BIO (01548.HK) announced that on December 10, 2024 (before the Hong Kong trading session on December 10), Legend Biotech released a press release, announcing the latest data from the Phase 3 study CARTITUDE-4. The study results indicate that in patients with relapsed or lenalidomide-refractory multiple myeloma who have previously received at least first-line treatment (including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)), compared to standard therapy (pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide...
Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
Tonight, Chinese concepts soared! The nasdaq Golden Dragon index surged by 10%, while fangdd network doubled directly.
Some analysis indicates that the Political Bureau meeting first mentioned stabilizing the stock and real estate markets, and the US stock market quickly rallied on china assets. The 3x Long FTSE china etf surged over 26%, the 2x Long china internet plus-related stocks rose over 22%, the 2x Long FTSE china 50 ETF increased over 17%, and the 2x Long 300etf gained nearly 15%.
Legend Biotech Analyst Ratings
Express News | Legend Biotech Corp : UBS Cuts Target Price to $65 From $75
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $83
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011